BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Graves' Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Graves' Disease\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07018323-10825@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT07018323)
DESCRIPTION:Imeroprubart\, phase 2\, Graves' Disease.\nStudy: A Study to As
 sess the Efficacy\, Safety\, and Tolerability of IMVT-1402 as Treatment fo
 r Adult Participants With Graves' Disease\nEstimated primary completion: M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/imeroprubart
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 18323
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06727604-10825@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT06727604)
DESCRIPTION:Imeroprubart\, phase 2\, Graves' Disease.\nStudy: A Study to As
 sess the Efficacy\, Safety\, and Tolerability of IMVT-1402 as Treatment fo
 r Adult Participants With Graves' Disease\nEstimated primary completion: J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/imeroprubar
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 727604
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286006-10825@assetmemo.bio
DTSTAMP:20261122T012610Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT07286006)
DESCRIPTION:Imeroprubart\, phase 2\, Graves' Disease.\nStudy: A Long-Term E
 xtension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD
 )\nEstimated primary completion: March 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/imeroprubart#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07286006
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
